- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
Patent holdings for IPC class A61K 31/573
Total number of patents in this class: 4555
10-year publication summary
|
394
|
411
|
438
|
437
|
458
|
457
|
464
|
399
|
324
|
206
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Janssen Biotech, Inc. | 1762 |
61 |
| Genentech, Inc. | 4099 |
60 |
| Chiesi Farmaceutici S.p.A. | 959 |
58 |
| The Regents of the University of California | 20720 |
43 |
| Celgene Corporation | 1411 |
37 |
| Sage Therapeutics, Inc. | 300 |
31 |
| Janssen Pharmaceutica N.V. | 3171 |
30 |
| Hoffmann-La Roche Inc. | 3783 |
28 |
| Regeneron Pharmaceuticals, Inc. | 4698 |
27 |
| Cassiopea S.P.A. | 55 |
26 |
| The Board of Trustees of the Leland Stanford Junior University | 6644 |
24 |
| Oculis Operations Sàrl | 46 |
24 |
| Mexichem Fluor, Sociedad Anonima de Capital Variable | 204 |
22 |
| AVM Biotechnology, LLC | 25 |
21 |
| ReveraGen Biopharma, Inc. | 32 |
21 |
| Allergan, Inc. | 2169 |
20 |
| Massachusetts Institute of Technology | 10239 |
20 |
| Bristol-myers Squibb Company | 4729 |
19 |
| Antecip Bioventures II LLC | 374 |
19 |
| Chugai Seiyaku Kabushiki Kaisha | 1422 |
19 |
| Other owners | 3945 |